Fig. 1 · Structure

Documents & Downloads

Paeoniflorin

Cat. No. A11907 CAS 23180-57-6
Paeoniflorin is a herbal constituent extracted from the root of Paeonia albiflora Pall.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vitro Studies

Paeoniflorin neither reduced BACH1 levels nor exhibited anti-invasive effects in KP FBXO22-KO spheroids embedded in collagen. In A549 cells, Paeoniflorin treatment reduced total, nuclear and cytoplasmic BACH1 protein levels. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Invasive Sprouting in KP FBXO22-KO Spheroids

Cell-based study · KP FBXO22-KO spheroids embedded in collagen [1]

Quantification of invasive sprouting in KP and KP FBXO22-KO spheroids embedded in collagen and treated with either vehicle (DMSO) or paeoniflorin 1000 μM for 48 h. In FBXO22-KO cells paeoniflorin treatment neither reduced BACH1 levels (Fig. 5D) nor exhibited anti-invasive effects (Fig. 5E). 16 h later cells were lysed and the levels of the indicated proteins were analysed by Western blot.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
invasive sproutingReported result in FBXO22-KO cells paeoniflorin treatment neither reduced BACH1 levels (Fig. 5D) nor exhibited anti-invasive effects (Fig. 5E). 16 h later cells were lysed and the levels of the indicated proteins were analysed by Western blot. Quantification of invasive sprouting in KP and KP FBXO22-KO spheroids embedded in collagen and treated with either vehicle (DMSO) or paeoniflorin 1000 μM for 48 h.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1000 μM
Exposure duration
48 h
Method
treated
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: Paeoniflorin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Use of the signature to identify novel BACH1 inhibitors (S192); Fig. 5 legend (S253, S254)

invasive sprouting: invasive sprouting; comparator: vehicle (DMSO) — Results > Use of the signature to identify novel BACH1 inhibitors (S192); Fig. 5 legend (S253, S254)

BACH1 Protein Levels in A549 Cells

Cell-based study · A549 [1]

A549 cells were treated with Paeoniflorin, with DMSO as the vehicle control. Treatment reduced total, nuclear and cytoplasmic BACH1 protein levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BACH1 protein levels normalised to TUBULIN levelsReported result reduced the levels of BACH1 (total, nuclear and cytoplasmic levels) in lung and breast cancer cell lines[1]

Literature-Reported Treatment Conditions

Exposure duration
16 h
Method
treated
Vehicle
DMSO
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: Paeoniflorin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Use of the signature to identify novel BACH1 inhibitors (S180); Fig. 4 legend (S241, S242, S243)

BACH1 protein levels normalised to TUBULIN levels: BACH1 protein levels normalised to TUBULIN levels; comparator: vehicle (DMSO) — Results > Use of the signature to identify novel BACH1 inhibitors (S180); Fig. 4 legend (S243)

In Vivo Studies

Paeoniflorin was administered by oral gavage to male Sprague-Dawley rats with nephrectomy-induced chronic renal failure. Compared with distilled-water-treated CRF controls, Paeoniflorin significantly and dose-dependently reduced serum creatinine. [2]

Serum Creatinine in Rats With Chronic Renal Failure

Animal study · male Sprague-Dawley (SD) rats; chronic renal failure (CRF) rat model; six rats in each group [2]

Male Sprague-Dawley rats with nephrectomy-induced chronic renal failure received Paeoniflorin by oral gavage. Compared with the distilled-water-treated nephrectomy control group, Paeoniflorin significantly and dose-dependently reduced serum creatinine.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum creatinineReported result PF significantly and dose-dependently reduced serum creatinine (SCr)[2]

Conditions shared by the study groups

Route
oral gavage
Treatment course
daily by oral gavage for 16 weeks; measured at baseline and weeks 4, 8, 12, and 16
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Paeoniflorin 25 mg/kg PF; 50 mg/kg PF5/6nx CRF group (treated with distilled water for 5/6nx model rats)PF significantly and dose-dependently reduced serum creatinine (SCr)[2]
Paeoniflorin 25 mg/kg PF; 50 mg/kg PF
Model: male Sprague-Dawley (SD) rats; chronic renal failure (CRF) rat model; six rats in each group
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Paeoniflorin

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animal experiments (S2, S8, S9); Results > PF exhibits renoprotective effects in models of renal dysfunction (S41, S43); Fig. 1 legend (S189)

Serum creatinine: Serum creatinine; comparator: 5/6nx CRF group (treated with distilled water for 5/6nx model rats) — Results > PF exhibits renoprotective effects in models of renal dysfunction (S43); Fig. 1 legend (S189)

Paeoniflorin 25 mg/kg PF; 50 mg/kg PF · Materials and methods > Animal experiments (S8, S9); Results > PF exhibits renoprotective effects in models of renal dysfunction (S43); Fig. 1 legend (S189)

Specifications

Manufacturer Adooq Bioscience
CAS Number 23180-57-6
Formula C23H28O11
Molecular Weight 480.46
SMILES
C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=CC=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (183.15 mM)
Water 88 mg/mL (183.15 mM)
Ethanol 88 mg/mL (183.15 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Klenja-Skudrinja D, Ali KX, Walker D, et al. Identification of a BACH1 lung cancer signature: A novel tool for understanding BACH1 biology and identifying new inhibitors. Redox Biol (2025). PMID: 40716152 DOI: 10.1016/j.redox.2025.103789 Source material
  2. [2] Li R, Xia J, Shi C, et al. Direct pharmacological targeting of Piezo1 by Paeoniflorin: a novel therapeutic approach for renal fibrosis. J Adv Res (2026). PMID: 40653265 DOI: 10.1016/j.jare.2025.07.015 Source material

Added to your cart

View Cart Checkout
Loading...